Haemophilia is a sex-linked recessive bleeding disorder which affects approximately 20 000 people in the United States and nearly 185 000 globally.
regular replacement with concentrates of FVIII experience a nearnormal lifespan 4 and quality of life by essentially averting all but a small number of bleeding events. 5 Despite the benefits, in severe cases, approximately 50% will have an annual bleeding rate (ABR) of more than two despite regular replacement of the missing clotting factor administered as prophylaxis to prevent bleeding. [5] [6] [7] [8] Among the barriers to achieving optimal outcomes is adherence to the FVIII dosing regimen which mandates frequent, intravenous injections of concentrates of FVIII 9, 10 and achieving circulating FVIII levels sufficient to prevent bleeding including with physical activity.
11
Even if adherence to a prophylaxis regimen is optimal, bleeding still occurs resulting in long-term morbidity, primarily from chronic synovitis and the development of debilitating joint disease. 8 In addition, the most feared and clinically significant complication of factor replacement is the development of alloantibodies directed against the exogenous FVIII molecules which inhibit the function of the replacement FVIII. 12 Inhibitors to FVIII occur in approximately 1/3 of those with severe haemophilia A, typically within the first 20 exposures to exogenous FVIII early in the first 2-3 years of life when venous access is a challenge. 13 The development of inhibitors to FVIII results in a substantial increase in the likelihood of morbidity due to uncontrollable bleeding.
14 Therefore, although current prophylactic treatment is highly effective in reducing the numbers of joint bleeding episodes, it does not completely eliminate them from occurring and therefore the long-term implication of even a very few bleeding events into joints is arthropathy over 25-30 years. 15 In addition to lack of complete efficacy, the burden of chronic, lifelong intravenous injections [16] [17] [18] and the economic burden of the disease and its treatment 19 make haemophilia an attractive target for innovative and potentially disruptive treatment strategies.
Moreover, approximately one third of patients with severe haemophilia A will develop an alloimmune response against the infused clotting factor which then inhibits the function of the administered factor concentrate increasing the likelihood of uncontrollable bleeding and increasing the morbidity of the disease. 20 Innovative strategies to meet these unmet needs have emerged and include pursuit of a genetic treatment that might be administered once in a lifetime that results in long-term, persistent FVIII expression to mitigate the need for regular infusions of clotting factor concentrates by achieving a level high enough to eliminate the risk of bleeding in patients with an active lifestyle. 21, 22 Other approaches include non-factor treatments which are administered subcutaneously at infrequent intervals. 23 Among these novel treatments, one, emicizumab-kxwh (emicizumab, Hemlibra, ACE910, RG6013, RO5534262), created by Chugai Pharmaceutical Co., Ltd. and codeveloped by Chugai, Hoffmann-LaRoche and Genentech, has gained regulatory approval in the United States. 24 Emicizumab is a humanized, asymmetric, bispecific, IgG4 monoclonal antibody designed to mimic the function of activated factor (F)VIII which may be missing or defective due to a gene mutation in F8 resulting in haemophilia A.
In order to put emicizumab into context of the many haemophilia novel therapies currently evolving, it is important to mention the recent report of Callaghan et al. 25 They have stated that although management of haemophilia has focused on replacement of the missing coagulation factor to prevent or treat bleeding, new technologies and insights into haemostasis, in addition to emicizumab, have driven the development of several promising new therapies for haemophilia. Tissue factor pathway inhibitor, the protein C/S system, and antithrombin are targets of novel compounds in development to alter the haemostatic balance and new approaches utilizing modified factor VIII molecules are being studied for prevention and eradication of inhibitor antibodies in haemophilia A. 25 The purpose of this article was to review the development and potential role for emicizumab in haemophilia treatment.
| ME THODS
A Cochrane Library and PubMed (MEDLINE) search related to the role of emicizumab was performed and analysed by both authors.
Only English language articles were retrieved. Where appropriate, scientific meeting abstracts and other sources of evidence were con- 
| RE SULTS
In total, 37 citations were retrieved and serve as the database for the literature reviewed herein.
| Overview
The potential benefits of a monoclonal antibody include a non-intravenous route of administration owing to the bioavailability of the molecule delivered into the subcutaneous space, increased procoagulant activity when administered prophylactically and because of its unique mechanism of action, efficacy in the absence or presence of inhibitory antibodies directed against FVIII. 26, 27 Emicizumab is manufactured using Chugai's proprietary Asymmetric Re-engineering 
| Mechanism of action
The prime function of factor FVIIIa is as a cofactor of FIXa in the tenase complex. Upon association with an anionic phospholipid surface, such as on the activated platelet, zymogen FX is converted to its enzymatic form, FXa. To achieve maximal activity, the tenase complex must assemble through interactions with FVIIIa, FIXa and FX. Procofactor FVIII must be activated through cleavage by throm- 
| Pharmacokinetics
The most important contribution of emicizumab is its improved phar- 
| Development path of emicizumab
Preclinical in vitro studies and studies in primate models of haemophilia demonstrated haemostatic effects.
29,31
In a non-human primate model of acquired haemophilia A, a single injection of emicizumab demonstrated both haemostatic activity and a prolonged therapeutic benefit with a half-life of Healthy subjects A total of 40 Japanese and 24 white subjects were randomized to receive a single subcutaneous injection of emicizumab (Japanese: 0.001, 0.01, 0.1, 0.3 or 1 mg/kg; white: 0.1, 0.3 or 1 mg/ kg; n = 6 per dose group) or placebo (n = 2 per dose group)
Emicizumab exhibited a linear PK profile and had a half-life of around 4-5 wk. In FVIII-neutralized plasma, emicizumab shortened the aPTT and increased peak height of thrombin generation in a dose-dependent manner. All complications were judged not to be serious and did not lead to any subject's withdrawal from the trial. Neither clinical findings nor laboratory abnormalities indicating hypercoagulability were observed. The PK and PD profiles of emicizumab were similar in healthy Japanese and white subjects suggesting that emicizumab will be an effective and convenient prophylactic treatment of haemophilia A Importantly, the molecule had no effect on the concentrations of either factor IX or factor X or their active forms. There was a dosedependent shortening of the activated partial thromboplastin time which was accentuated when FVIII activity was first neutralized ex The clinical development programme for emicizumab included the five phase 3 trials (HAVEN-1, HAVEN-2, HAVEN-3, HAVEN-4, HAVEN-5 and STASEY) summarized in Tables 1  26,29, HOHOEMI (JapicCTI-173710) is a trial initiated in Japan to study emicizumab in 13 children younger than 12 years of age including previously untreated patients without inhibitors to FVIII.
Emicizumab will be administered at doses of either 3 mg/kg every 2 weeks or 6 mg/kg monthly. No data are available from this trial.
| Adverse events
The most important adverse events are the following: injection site reactions (19%), pyrexia (7%), headache (15%), diarrhoea (6%), 
| Unsolved issues and dosage in special cases
In The Bethesda assay utilizing a bovine reagentbased FVIII chromogenic assay must be used. 51 The standard dose of emicizumab is 3 mg/kg by subcutaneous injection once weekly for the first 4 weeks followed by 1.5 mg/kg has been approved in the United States for use as routine prophylaxis administered once a week to prevent or reduce the frequency of bleeding episodes in adults and children ≥12 years of age with haemophilia A with FVIII inhibitors. Regulatory approval in several countries around the world, including in the EU and Japan is awaited.
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